Claros Technologies (Claros), a global leader in permanent PFAS destruction technology, today announced the successful completion of a commercial-scale pilot of its ClarosTechUV system at the flagship Swiss manufacturing campus of Bachem AG (Bachem) in Bubendorf, Switzerland. Bachem is one of the world's leading manufacturers of peptide and oligonucleotide active pharmaceutical ingredients (APIs), including semaglutide, the API used in blockbuster GLP-1 therapies, widely used for weight management and type 2 diabetes.
"This relationship with Bachem represents a defining milestone for Claros and an important step forward for the global pharmaceutical industry," said Michelle Bellanca, CEO and Co-Founder of Claros Technologies. "As pharmaceutical manufacturing expands, particularly around peptide therapeutics and GLP-1 medicines, the industry is increasingly confronting how to address ultra-short-chain PFAS such as TFA in industrial wastewater. Bachem is demonstrating the kind of leadership that will define the future of pharmaceutical and industrial manufacturing by proactively deploying ClarosTechUV™ technology to destroy TFA at the source. We are incredibly proud to collaborate with one of the world's leading peptide manufacturers on this important work."
Bachem is a global leader in the development and manufacture of peptide and oligonucleotide APIs, supplying pharmaceutical and biotechnology companies around the world. As demand for peptide therapeutics, including those used in GLP-1 medicines, and other critical medications continues to accelerate, the growth of pharmaceutical manufacturing is bringing increasing attention to environmental stewardship.